Search research articles
Contact Us
Filters
Showing results (81-90 of 107) with videos related to
Page
of 11
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 24, 2020
Randomized Trial Comparing Double Versus Triple Bortezomib-Based Regimen in Patients With Multiple Myeloma and Acute Kidney Injury Due to Cast Nephropathy
Frank Bridoux, Bertrand Arnulf, Lionel Karlin, et al.
British Journal of Haematology
|
June 21, 2019
Daratumumab and dexamethasone is safe and effective for triple refractory myeloma patients: final results of the IFM 2014-04 (Etoile du Nord) trial
Eileen M Boyle, Xavier Leleu, Marie-Odile Petillon, et al.
Leukemia & Lymphoma
|
July 13, 2017
Heavy + light chain analysis to assign myeloma response is analogous to the IMWG response criteria
Guillemette Fouquet, Kym Ie Snell, Stéphanie Guidez, et al.
Blood
|
January 16, 2013
Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du Myélome 2009-02
Xavier Leleu, Michel Attal, Bertrand Arnulf, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 27, 2016
Bortezomib, Doxorubicin, Cyclophosphamide, Dexamethasone Induction Followed by Stem Cell Transplantation for Primary Plasma Cell Leukemia: A Prospective Phase II Study of the Intergroupe Francophone du Myélome
Bruno Royer, Stéphane Minvielle, Momar Diouf, et al.
American Journal of Hematology
|
December 23, 2015
Impact of eculizumab treatment on paroxysmal nocturnal hemoglobinuria: a treatment versus no-treatment study
Michael Loschi, Raphael Porcher, Fiorenza Barraco, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 26, 2013
Chromosomal abnormalities are major prognostic factors in elderly patients with multiple myeloma: the intergroupe francophone du myélome experience
Hervé Avet-Loiseau, Cyrille Hulin, Loic Campion, et al.
Haematologica
|
November 16, 2014
Phase II study of bendamustine, bortezomib and dexamethasone as second-line treatment for elderly patients with multiple myeloma: the Intergroupe Francophone du Myelome 2009-01 trial
Philippe Rodon, Cyrille Hulin, Brigitte Pegourie, et al.
Annals of Hematology
|
January 14, 2018
Salvage therapy post pomalidomide-based regimen in relapsed/refractory myeloma
Guillemette Fouquet, Lionel Karlin, Margaret Macro, et al.
Haematologica
|
April 15, 2014
Age is a prognostic factor even among patients with multiple myeloma younger than 66 years treated with high-dose melphalan: the IFM experience on 2316 patients
Marie-Lorraine Chretien, Benjamin Hebraud, Valérie Cances-Lauwers, et al.
Page
of 11
Search research articles
Search
Showing results (81-90 of 107) with videos related to
Sort By:
Page
of 11
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 24, 2020
Randomized Trial Comparing Double Versus Triple Bortezomib-Based Regimen in Patients With Multiple Myeloma and Acute Kidney Injury Due to Cast Nephropathy
Frank Bridoux, Bertrand Arnulf, Lionel Karlin, et al.
British Journal of Haematology
|
June 21, 2019
Daratumumab and dexamethasone is safe and effective for triple refractory myeloma patients: final results of the IFM 2014-04 (Etoile du Nord) trial
Eileen M Boyle, Xavier Leleu, Marie-Odile Petillon, et al.
Leukemia & Lymphoma
|
July 13, 2017
Heavy + light chain analysis to assign myeloma response is analogous to the IMWG response criteria
Guillemette Fouquet, Kym Ie Snell, Stéphanie Guidez, et al.
Blood
|
January 16, 2013
Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du Myélome 2009-02
Xavier Leleu, Michel Attal, Bertrand Arnulf, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 27, 2016
Bortezomib, Doxorubicin, Cyclophosphamide, Dexamethasone Induction Followed by Stem Cell Transplantation for Primary Plasma Cell Leukemia: A Prospective Phase II Study of the Intergroupe Francophone du Myélome
Bruno Royer, Stéphane Minvielle, Momar Diouf, et al.
American Journal of Hematology
|
December 23, 2015
Impact of eculizumab treatment on paroxysmal nocturnal hemoglobinuria: a treatment versus no-treatment study
Michael Loschi, Raphael Porcher, Fiorenza Barraco, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 26, 2013
Chromosomal abnormalities are major prognostic factors in elderly patients with multiple myeloma: the intergroupe francophone du myélome experience
Hervé Avet-Loiseau, Cyrille Hulin, Loic Campion, et al.
Haematologica
|
November 16, 2014
Phase II study of bendamustine, bortezomib and dexamethasone as second-line treatment for elderly patients with multiple myeloma: the Intergroupe Francophone du Myelome 2009-01 trial
Philippe Rodon, Cyrille Hulin, Brigitte Pegourie, et al.
Annals of Hematology
|
January 14, 2018
Salvage therapy post pomalidomide-based regimen in relapsed/refractory myeloma
Guillemette Fouquet, Lionel Karlin, Margaret Macro, et al.
Haematologica
|
April 15, 2014
Age is a prognostic factor even among patients with multiple myeloma younger than 66 years treated with high-dose melphalan: the IFM experience on 2316 patients
Marie-Lorraine Chretien, Benjamin Hebraud, Valérie Cances-Lauwers, et al.
Page
of 11